ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2024年11月27日

查看全文
  • Zhenyan Wang,
  • Junyang Yang,
  • Lin Wang,
  • Jiangrong Wang,
  • Yinzhong Shen,
  • Jun Chen,
  • Tangkai Qi,
  • Jianjun Sun,
  • Wei Song,
  • Yang Tang,
  • Shuibao Xu,
  • Li Liu,
  • Renfang Zhang

摘要

This study aimed to evaluate the efficacy and safety of dolutegravir plus lamivudine (DTG/3TC) in antiretroviral treatment (ART)-experienced people living with HIV (PLWH). A total of 303 PLWH in Shanghai, China, who switched from triple ART to DTG/3TC between January 2019 and June 2022, with a minimum ART duration of 6 months, were retrospectively enrolled. More than 95% of PLWH maintained viral suppression with no significant changes in CD4 counts 12 months after switching. Patients transitioning from non-tenofovir (TDF)-based regimens demonstrated more pronounced improvements in lipid profiles, while those previously on TDF-based regimens showed greater enhancements in bone metabolism.